Zanubrutinib monotherapy in CD79B-mutated relapsed or refractory diffuse large B-cell lymphoma: A multicenter Phase 2 study - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Zanubrutinib Alone for CD79B-Mutated Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Multicenter Phase 2 Trial

  • By

  • Li Wang

  • Keshu Zhou

  • Fei Li

  • Qingyuan Zhang

  • Hui Zhou

  • Ou Bai

  • Liping Su

  • Chunhong Hu

  • Zhi-Ming Li

  • Kaiyang Ding

  • Qunyi Guo

  • Xiaoling Li

  • Xiaoxi Zhou

  • Wenjuan Yu

  • Shuhua Yi

  • Zhixia Wei

  • Wenbin Qian

  • Feiheng Chen

  • Guohui Cui

  • Zhiyu Liang

  • Qingchao Zeng

  • Jiaoyan Lyu

  • Yang Liu

  • Pan Zhang

  • Zhirong Shen

  • Zaixing Shi

  • Jing Rong

  • Wei-Li Zhao

  • October 15, 2026

Share

  • 1

    This open-label, single-arm phase 2 trial evaluated zanubrutinib monotherapy in 65 Chinese adults with CD79B-mutated relapsed or refractory DLBCL.

  • 2

    After a median 13.9 months of observation, the investigator-determined overall response rate was 46.2%, including a complete response rate of 29.2%.

  • 3

    Median duration of response was 22.7 months, median progression-free survival was 4.3 months, and median overall survival was 18.1 months.

  • 4

    Responses occurred mainly in non-GCB disease; no objective responses were observed in the small GCB subgroup.

  • 5

    Grade 3 or higher treatment-emergent adverse events occurred in 43.1% of patients, with pneumonia the most frequent severe event at 9.2%.

Original Source(s)

Zanubrutinib monotherapy in CD79B-mutated relapsed or refractory diffuse large B-cell lymphoma: A multicenter Phase 2 study

  • by Li Wang, Keshu Zhou, Fei Li, Qingyuan Zhang, Hui Zhou, Ou Bai, Liping Su, Chunhong Hu, Zhi-Ming Li, Kaiyang Ding, Qunyi Guo, Xiaoling Li, Xiaoxi Zhou, Wenjuan Yu, Shuhua Yi, Zhixia Wei, Wenbin Qian, Feiheng Chen, Guohui Cui, Zhiyu Liang, Qingchao Zeng, Jiaoyan Lyu, Yang Liu, Pan Zhang, Zhirong Shen, Zaixing Shi, Jing Rong, Wei-Li Zhao

  • October 15, 2026

Related Content

Defensive responses to the U.S. Surgeon General’s alcohol-cancer advisory: A topic modeling analysis of TikTok comments

Breast Cancer De-Escalation: Defining When Less Treatment Is Enough

The evolution of breast cancer care is increasingly challenging a long-standing assumption in oncology: that greater treatment intensity necessarily translates into better outcomes.

  • by

  • October 13, 2026

  • 9 min
Daily-life dynamics of general and cognitive fatigue in childhood cancer survivors: An experience sampling and wearable study